Phaseline

Targets › IDS

IDS (Iduronate 2-sulfatase): drug programs, companies and trials

5 programs from 4 companies in 7 trials: 4 Phase 2, 2 Phase 1, 1 Phase 3; Metabolic and endocrine; next expected readout Jun 2027.

Lysosomal enzyme involved in the degradation pathway of dermatan sulfate and heparan sulfate. (UniProt, P22304)

Open in Phaseline: the race on IDS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
REGENXBIORGX-121-3102
Recombinant adeno-associated virus serotype 9 (AAV9) delivering human iduronate-2-sulfatas
IDSPhase 3MPS II; Mucopolysaccharidosis Type II (MPS II)Apr 2028
Denali Therapeuticstividenofusp alfa (DNL310)
CNS-penetrant iduronate 2-sulfatase enzyme replacement therapy
IDSPhase 2Mucopolysaccharidosis IIDec 2027
TakedaElaprase
Iduronate-2-sulfatase (IDS) enzyme replacement therapy administered intravenously
IDSPhase 2Hunter SyndromeJan 2029
TakedaIdursulfase-IT
Iduronate-2-sulfatase (IDS) enzyme replacement therapy administered intrathecally
IDSPhase 2Hunter SyndromeJan 2029
GC BiopharmaGC1123
Idursulfase-β (Hunter syndrome enzyme replacement therapy)
IDSPhase 1Mucopolysaccharidosis IIJun 2027

Conditions

Mucopolysaccharidosis II (3) Hunter Syndrome (2) MPS II (1) Mucopolysaccharidosis Type II (MPS II) (1)

Modalities

protein or peptide (3), mixed (1), other (1)

Companies

Takeda (2) GC Biopharma (1) Denali Therapeutics (1) REGENXBIO (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.